Why ICON (ICLR) Is Up 16.5% After 2025 Earnings, Accounting Issues And New 2026 Outlook – And What's Next

Simply Wall St.06-01

In late May 2026, ICON plc reported full-year 2025 results showing sales of US$8.25 billion, a sharp drop in net income to US$229.34 million, disclosed multi-year revenue recognition issues, completed...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640930919?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-06-01 16:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640930919","market":"us","top_or_hot":-1,"title":"Why ICON (ICLR) Is Up 16.5% After 2025 Earnings, Accounting Issues And New 2026 Outlook – And What's Next","media":"Simply Wall St.","content":"<div>\n<p>In late May 2026, ICON plc reported full-year 2025 results showing sales of US$8.25 billion, a sharp drop in net income to US$229.34 million, disclosed multi-year revenue recognition issues, completed...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/why-icon-iclr-is-up-165-after-2025-earnings-accounting-issue\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why ICON (ICLR) Is Up 16.5% After 2025 Earnings, Accounting Issues And New 2026 Outlook – And What's Next</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy ICON (ICLR) Is Up 16.5% After 2025 Earnings, Accounting Issues And New 2026 Outlook – And What's Next\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-01 16:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/why-icon-iclr-is-up-165-after-2025-earnings-accounting-issue><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late May 2026, ICON plc reported full-year 2025 results showing sales of US$8.25 billion, a sharp drop in net income to US$229.34 million, disclosed multi-year revenue recognition issues, completed...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/why-icon-iclr-is-up-165-after-2025-earnings-accounting-issue\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICON","symbol_name":"Icon Energy Corp.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/why-icon-iclr-is-up-165-after-2025-earnings-accounting-issue","article_id":"2640930919","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/why-icon-iclr-is-up-165-after-2025-earnings-accounting-issue","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640930919","pubTimestamp":1780302054,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late May 2026, ICON plc reported full-year 2025 results showing sales of US$8.25 billion, a sharp drop in net income to US$229.34 million, disclosed multi-year revenue recognition issues, completed a US$750.01 million buyback program, updated 2026 revenue guidance to US$7.85–8.15 billion, and announced several board changes.\nWhile ICON is working through accounting control weaknesses and lower profitability, management highlighted strong Q4 2025 net bookings growth, a focus on...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ICON":"Icon Energy Corp.","ICLR":"ICON plc"},"translate_title":"为什么ICON(ICLR)在2025年盈利、会计问题和新的2026年展望之后上涨16.5%-以及下一步是什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICON":1.5,"ICLR":1.5},"content_text":"In late May 2026, ICON plc reported full-year 2025 results showing sales of US$8.25 billion, a sharp drop in net income to US$229.34 million, disclosed multi-year revenue recognition issues, completed a US$750.01 million buyback program, updated 2026 revenue guidance to US$7.85–8.15 billion, and announced several board changes. While ICON is working through accounting control weaknesses and lower profitability, management highlighted strong Q4 2025 net bookings growth, a focus on higher-growth lab and early-phase services, and the Symphony Health divestiture as steps to refocus the business mix. We’ll now examine how ICON’s newly disclosed accounting control weaknesses and revenue guidance reshape the company’s existing investment narrative. The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementICON Investment Narrative RecapTo own ICON today, you need to believe its core CRO franchise and Q4 2025 bookings strength can offset near term pressure from lower earnings, revenue recognition issues, and softer 2026 guidance. The most important short term catalyst is whether strong net bookings translate into cleaner, higher quality revenue, while the biggest risk is that accounting control weaknesses and trial volatility keep weighing on margins and confidence. The latest results materially sharpen both sides of that trade off. Among the recent announcements, the 2026 revenue guidance of US$7.85–8.15 billion stands out as most relevant. It reframes expectations around near term growth, especially after the 2023–2024 revenue overstatements, and puts more weight on ICON’s ability to convert its higher lab and early phase focus, the Advarra partnership, and Symphony Health divestiture into stable, transparent revenue that can support any future capital returns. But beneath the apparent booking strength and new guidance, there is a developing risk around earnings quality and backlog that investors should be aware of… Read the full narrative on ICON (it's free!)ICON’s narrative projects $8.4 billion revenue and $666.8 million earnings by 2029. This requires 1.4% yearly revenue growth and about a $67 million earnings increase from $599.5 million today.Uncover how ICON's forecasts yield a $135.07 fair value, in line with its current price.Exploring Other PerspectivesICLR 1-Year Stock Price Chart Some of the lowest analysts were already cautious, assuming roughly flat US$8.2 billion revenue and lower margins by 2029, and the new control and backlog questions could either validate that more pessimistic view or prompt a rethink of what earnings power really looks like here.Explore 5 other fair value estimates on ICON - why the stock might be worth 45% less than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your ICON research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free ICON research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ICON's overall financial health at a glance.Ready For A Different Approach?Opportunities like this don't last. These are today's most promising picks. Check them out now:Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Uncover the next big thing with 23 elite penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640930919","isCrawlerRequest":true}